« Return to News | R&D Trends

Roche, AstraZeneca launch early research data-sharing consortium

Tuesday, July 2, 2013 01:24 PM

Roche and AstraZeneca are collaborating to share early research data related to drug design to further accelerate discovery of high-quality compounds with an increased chance of clinical success.

Using a dedicated technology called Matched Molecular Pair Analysis (MMPA), modifications will be identified that companies can apply to their compound structures to improve their metabolism, pharmacokinetics or safety without divulging confidential information about their chemical structures. This gives both companies the opportunity to reapply useful medicinal chemistry know-how embedded in their combined databases of experimental results, to identify potential new drug candidates using fewer rounds of design, synthesis and testing.

"AstraZeneca has taken multiple steps to both open our compound libraries to those wishing to find new chemistries for early drug discovery and to share compound-related datasets that will allow our industry to speed the discovery of new medicines," said Mike Snowden, head of Discovery Sciences in Innovative Medicines and Early Development (IMED), which initiated the collaboration.

The data-sharing will be managed through an intermediary company, MedChemica, which has expertise in MMPA. The consortium is open to other large companies to add their knowledge, to gain access to and enhance the resource.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.